Art Reidel is a Partner in the Band's Acorn Fund and one of the Life Science/Biotech Screening Committee members. Art has helped build and scale profitable businesses in the electronic design automation, pharmaceutical software, semiconductor, and communications industries for more than 30 years. He was most recently CEO of Scintera, a mixed signal wireless IC company he joined in 2006. Prior to joining Scintera, he was co-founder, chairman and CEO of Pharsight Corporation (now part of Tripos International) where he led its IPO in August 2000. He was also president and CEO of Sunrise Test Systems (acquired by Viewlogic Systems) and has held executive positions with Weitek, Interactive Training Systems, and Schlumberger Computer-Aided Systems. In addition to management roles, Art is well known in the investment community. Art is a partner with Horizon Ventures, and was a venture partner at Lightspeed Venture Partners from 2003 through 2005 where he provided management assistance to portfolio companies and was responsible for several new investments. He earlier served as a general partner at ABS Ventures for 7 years where he invested in and was a director of numerous technology-based companies.